- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01550549
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Avid has previously developed a florbetapir-PET scan binary read methodology and training program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369), 18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies, training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of this training program suitable for web-based distribution. Nuclear medicine physicians will complete the automated training program then read the florbetapir-PET images from 151 subjects with repeat readings of 33 randomly selected images. Readers will rate each case as either positive for significant tracer accumulation in cortical gray matter or negative for significant tracer accumulation in cortical gray matter. The inter-rater reliability, sensitivity and specificity of the readers will be evaluated.
The primary image set for determination of inter-reader agreement is comprised of images from 119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20 with mild cognitive impairment) MCI, 20 with AD.
Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients that were not used in the training program (n=32); 13 of these 32 scans presented for repeat reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased the number of unique cases in the validation dataset to 151 scans with 33 scans repeated yielding a total of 184 scans reviewed by the readers.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Eligibility for subjects scans to be used in this study is determined by subject's eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).
Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- Have probable AD per National Institute of Neurological and Communication Disorders and Stroke (NINCDS) criteria
- Mini mental state exam (MMSE) score between 10 and 24 inclusive
Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):
- Male or female at least 50 years of age
- Complaints of memory or cognitive decline corroborated by an informant
- Clinical dementia rating of 0.5
- No obvious cause for cognitive impairment (eg, head trauma or stroke)
- Cognitive impairment onset within the past year
- MMSE score greater than 24
Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- MMSE score greater than or equal to 29 and cognitively normal by informant report and psychometric test battery at screening
Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):
- Male or female 18 years or older
- Projected life expectancy of less than 6 months
- Consent to brain donation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Enkelt
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Inter-rater Reliability
Tidsramme: Scan acquired 50-60 min post-injection
|
Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa.
All scans were read in a blinded fashion without access to clinical information.
|
Scan acquired 50-60 min post-injection
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Tidsramme: at autopsy, within 2 years of scan
|
Calculated as the percent of true positives which are correctly identified
|
at autopsy, within 2 years of scan
|
|
Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Tidsramme: at autopsy, within 2 years of scan
|
Calculated as the percent of true negatives which are correctly identified
|
at autopsy, within 2 years of scan
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Median Sensitivity and Specificity vs. CERAD Diagnosis
Tidsramme: Baseline scan
|
Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).
|
Baseline scan
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 18F-AV-45-PT01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Neurodegenerative sygdomme
-
University of OviedoUniversity of LeonAfsluttet
-
University of PennsylvaniaAvid RadiopharmaceuticalsRekruttering
-
ACADIA Pharmaceuticals Inc.AfsluttetNeuropsykiatriske symptomer relateret til neurodegenerativ sygdomForenede Stater, Den Russiske Føderation, Serbien, Polen, Georgien, Tjekkiet, Bulgarien, Colombia, Mexico, Rumænien, Sydafrika, Ukraine
-
IRCCS San RaffaeleAktiv, ikke rekrutterendeMild kognitiv svækkelse (MCI) | Neurodegenerativ sygdom | Neurodegenerativ demens | AMCI - Amnestic Mild Cognitive ImpairmentItalien
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ospedale San Luigi Gonzaga, Orbassano; Università di Torino, TorinoRekrutteringNeurodegenerativ demens | DemenssygdommeItalien
-
ACADIA Pharmaceuticals Inc.AfsluttetNeuropsykiatriske symptomer relateret til neurodegenerativ sygdomSerbien, Forenede Stater, Polen, Georgien, Den Russiske Føderation, Bulgarien, Colombia, Tjekkiet, Mexico, Rumænien, Sydafrika, Ukraine
-
University of Illinois at Urbana-ChampaignRekrutteringVoksne | Mindfulness | EEG | Neurodegenerativ sygdomForenede Stater
-
National Institute of Neurological Disorders and...Afsluttet
-
Tianjin Medical UniversityTianjin Medical University General HospitalRekrutteringTauopatier | Neurodegenerativ sygdom | Alzheimers sygdomKina
-
Oriental Neurosurgery Evidence-Based-Study TeamUkendtNeurodegenerativ demensKina
Kliniske forsøg med florbetapir F 18
-
Brigham and Women's HospitalAfsluttetHjerte amyloidoseForenede Stater
-
Avid RadiopharmaceuticalsTrukket tilbageAlzheimers sygdomJapan
-
Avid RadiopharmaceuticalsAfsluttetProgressiv kognitiv tilbagegangForenede Stater
-
Avid RadiopharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS); National...AfsluttetParkinsons sygdomForenede Stater
-
Avid RadiopharmaceuticalsAfsluttetAlzheimers sygdomForenede Stater
-
Avid RadiopharmaceuticalsAfsluttetAlzheimers sygdom
-
Avid RadiopharmaceuticalsAfsluttetMild kognitiv svækkelse | Alzheimers sygdomForenede Stater
-
Chang Gung Memorial HospitalUkendt
-
Avid RadiopharmaceuticalsEli Lilly and CompanyAfsluttet
-
Avid RadiopharmaceuticalsAfsluttetNeurodegenerative sygdomme | Alzheimers sygdom | Mild kognitiv svækkelseForenede Stater